But from our perspective, underlying growth remains prevalent throughout Johnson & Johnson's portfolio, and we think its pharmaceutical portfolio remains a bright spot. Johnson & Johnson reported 2015 second-quarter results July 14. Though the healthcare and consumer goods giant experienced quarterly revenue and adjusted earnings-per-share declines of 8.8% and 3.9% during the period, respectively, both numbers beat consensus estimates.